Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade

NCT04675827 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT04675827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04675827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Terminated
Start date
January 17, 2022
Completion date
November 26, 2024
Enrollment
139 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

er-negative breast cancer, her2-positive breast cancer, node-negative breast cancer, pr-negative breast cancer